Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
The UK authorization of Molnupiravir for mild/moderate COVID-191 says a lot about the current COVID-19 derangement syndrome. Molnupiravir’s efficacy is marginal, but its mutagenicity and carcinogenicity are real. The tidbits of information published by the UK’s MHRA include bone marrow toxicity discovered in some early trials, something suggested earlier in an article2 on this site. Thus, Molnupiravir is likely to cause leukemia.
The re-analysis of the data in Merck’s press release from October3, suggests that the announced results show much lower efficacy than claimed, even without questioning the conduct of the trial and reporting. Merck’s failure to publish that data is alarming. Merck also failed to disclose the outcomes from patients who were recruited after the cut-off date for the intermediate review.
The UK authorization also reveals that the population in Merck’s trial was younger and less at risk than the general population. When treated with Molnupiravir, the trial population had worse outcome than the comparable general population not...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).